The increasing interest in potent weight management has led to considerable research into groundbreaking treatments. Recently , Retatrutide, a twin-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist , has shown positive results in clinical trials, indicating potential for considerable weig